Toxicological Research

  • 제29권3호
  • /
  • Pages.217-219
  • /
  • 2013
  • /
  • 1976-8257(pISSN)
  • /
  • 2234-2753(eISSN)
한국독성학회 (Korean Society of Toxicology & Korea Environmental Mutagen Society)
권호 표지
DOI QR코드

DOI QR Code

Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay

  • 투고 : 2013.09.26
  • 심사 : 2013.09.29
  • 발행 : 2013.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 ${\mu}g$/plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.

키워드

참고문헌

  1. He, J. and Whelton, P.K. (1997) Epidemiology and prevention of hypertension. Med. Clin. North Am., 81, 1077-1097. https://doi.org/10.1016/S0025-7125(05)70568-X
  2. Whelton, P.K. (1994) Epidemiology of hypertension. Lancet, 344, 101-106. https://doi.org/10.1016/S0140-6736(94)91285-8
  3. Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K. and He, J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet, 365, 217-223. https://doi.org/10.1016/S0140-6736(05)17741-1
  4. Brunner, H.R. (2006) Olmesartan medoxomil: current status of its use in monotherapy. Vasc. Health Risk Manage., 2, 327-340. https://doi.org/10.2147/vhrm.2006.2.4.327
  5. Fletcher, A.E., Palmer, A.J. and Bulpitt, C.J. (1994) Cough with angiotensin converting enzyme inhibitors: how much of a problem? J. Hypertens. Suppl., 12, S43-S47.
  6. Vleeming, W., van Amsterdam, J.G., Stricker, B.H. and de Wildt, D.J. (1998) ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf., 18, 171-188. https://doi.org/10.2165/00002018-199818030-00003
  7. Warner, G.T. and Jarvis, B. (2002) Olmesartan medoxomil. Drugs, 62, 1354-1356. https://doi.org/10.2165/00003495-200262090-00009
  8. Mizuno, M., Sada, T., Ikeda, M., Fukuda, N., Miyamoto, M., Yanagisawa, H. and Koike, H. (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol., 285, 181-188. https://doi.org/10.1016/0014-2999(95)00401-6
  9. OECD/OCDE. (1997) OECD guidelines for the testing of chemicals (No. 471), Bacterial Reverse Mutation Test, pp. 1-11.
  10. Norwood, D., Branch, E.I., Smith, B. and Honeywell, M. (2002) Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast., 27, 611-618.
  11. Schwocho, L.R. and Masonson, H.N. (2001). Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J. Clin. Pharmacol., 41, 515-527. https://doi.org/10.1177/00912700122010393
  12. Puchler, K., Nussberger, J., Laeis, P., Wittem, P.U. and Brunner, H.R. (1997) Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist in saltrestricted hypertensive patients. J. Hypertens., 15, 1809-1812. https://doi.org/10.1097/00004872-199715120-00094
  13. Brambilla, G. and Martelli, A. (2006) Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat. Res., 612, 115-149. https://doi.org/10.1016/j.mrrev.2005.12.002